NUCLIDIUM receives second Innosuisse grant for its precision imaging platform
Nuclidium has won a second Innosuisse Grant of €800.000 to improve treatment of carcinomas via precision imaging of the tumour microenvironment with a novel Copper-61-based PET tracer. Our Kalios program is targeting cells in the tumor microenvironment called cancer-associated fibroblasts, which are present in epithelial tumours such as breast and lung cancer and are not present in healthy tissues.
The European Innovation Council (EIC) has awarded Nuclidium with its Accelerator grant of €2,5 million to develop novel, broadly available Copper-based PET tracers for the diagnosis of a broad range of cancer indications.
Innosuisse has awarded Nuclidium with a €1 million grant to further advance its development of a proprietary platform of novel PET tracers based on Copper-61.